Robbins LLP Is Investigating the Officers and Directors of Agios Pharmaceuticals, Inc. (AGIO) on Behalf of Shareholders

Robbins LLP is investigating whether certain officers and directors of Agios Pharmaceuticals, Inc. (NASDAQGS: AGIO) violated federal securities laws by issuing materially misleading business information to the investing public. Agios engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States.

Agios Stock Declines After Announcing Occurrence of Serious Adverse Event

At the 2016 American Society of Hematology meeting, Agios revealed information about its AG-519 molecule, which is used to treat pyruvate kinase deficiency. Agios reported that after a dose of 300 mg of AG-519, a serious adverse event of drug-related cholestatic hepatitis occurred. Agios further stated that a case of Grade 2 thrombocytopenia—a reduction of platelets in blood cells—was found in a patient receiving AG-519. On this news, Agios's stock fell by 18% to close at $46.72 per share on December 7, 2016.

Agios Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsllp.com, or you can complete the form below and we will contact you directly.